Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$21.91
-1.6%
$24.62
$15.42
$29.55
$1.04B1.93375,729 shs529,574 shs
InMode Ltd. stock logo
INMD
InMode
$14.92
+0.1%
$17.68
$13.68
$19.85
$1.04B1.961.18 million shs870,722 shs
MiMedx Group, Inc. stock logo
MDXG
MiMedx Group
$6.68
+0.7%
$7.69
$5.47
$10.14
$983.67M1.74694,787 shs373,721 shs
ZimVie Inc. stock logo
ZIMV
ZimVie
$9.39
+1.5%
$11.55
$8.56
$22.40
$261.48M2.14223,715 shs103,687 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.00%+0.05%-14.01%-16.18%+44.72%
InMode Ltd. stock logo
INMD
InMode
0.00%+0.27%-20.00%-11.14%-14.50%
MiMedx Group, Inc. stock logo
MDXG
MiMedx Group
0.00%-2.41%-17.49%-26.81%+5.45%
ZimVie Inc. stock logo
ZIMV
ZimVie
0.00%+2.62%-21.03%-34.29%-38.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.2539 of 5 stars
3.51.00.00.02.72.50.6
InMode Ltd. stock logo
INMD
InMode
2.4481 of 5 stars
3.21.00.00.02.71.71.9
MiMedx Group, Inc. stock logo
MDXG
MiMedx Group
3.1738 of 5 stars
3.52.00.00.02.82.51.9
ZimVie Inc. stock logo
ZIMV
ZimVie
2.5928 of 5 stars
3.53.00.00.02.81.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.00
Buy$31.1742.25% Upside
InMode Ltd. stock logo
INMD
InMode
2.40
Hold$21.2542.43% Upside
MiMedx Group, Inc. stock logo
MDXG
MiMedx Group
3.00
Buy$12.0079.78% Upside
ZimVie Inc. stock logo
ZIMV
ZimVie
3.00
Buy$19.50107.67% Upside

Current Analyst Ratings Breakdown

Latest ZIMV, INMD, BLFS, and MDXG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/14/2025
InMode Ltd. stock logo
INMD
InMode
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$16.00 ➝ $15.00
4/10/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$16.00
4/9/2025
InMode Ltd. stock logo
INMD
InMode
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/9/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/9/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
3/13/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
3/6/2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$27.00 ➝ $30.00
2/27/2025
MiMedx Group, Inc. stock logo
MDXG
MiMedx Group
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$13.00 ➝ $13.00
2/27/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
2/5/2025
InMode Ltd. stock logo
INMD
InMode
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$26.00 ➝ $29.00
2/4/2025
InMode Ltd. stock logo
INMD
InMode
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
(Data available from 4/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$82.25M12.65N/AN/A$7.67 per share2.86
InMode Ltd. stock logo
INMD
InMode
$394.82M2.63$1.43 per share10.40$10.12 per share1.47
MiMedx Group, Inc. stock logo
MDXG
MiMedx Group
$348.88M2.82$0.16 per share41.75$0.98 per share6.81
ZimVie Inc. stock logo
ZIMV
ZimVie
$449.75M0.58$3.39 per share2.77$15.43 per share0.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$66.43M-$0.50N/AN/AN/A-38.98%-6.61%-5.54%5/8/2025 (Estimated)
InMode Ltd. stock logo
INMD
InMode
$181.27M$2.356.358.20N/A45.91%18.25%16.33%4/28/2025 (Estimated)
MiMedx Group, Inc. stock logo
MDXG
MiMedx Group
$58.23M$0.2812.1420.86N/A23.86%26.21%18.15%4/30/2025 (Estimated)
ZimVie Inc. stock logo
ZIMV
ZimVie
-$393.28M-$0.95N/AN/A-77.31%2.90%1.17%5/14/2025 (Estimated)

Latest ZIMV, INMD, BLFS, and MDXG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.03N/AN/AN/A$22.22 millionN/A
4/30/2025Q1 2025
MiMedx Group, Inc. stock logo
MDXG
MiMedx Group
$0.06N/AN/AN/A$86.32 millionN/A
4/28/2025Q1 2025
InMode Ltd. stock logo
INMD
InMode
$0.45N/AN/AN/A$82.21 millionN/A
3/3/2025Q4 2024
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.06$0.26+$0.32$0.26$21.73 million$22.71 million
2/26/2025Q4 2024
MiMedx Group, Inc. stock logo
MDXG
MiMedx Group
$0.07$0.07N/A$0.05$89.42 million$92.91 million
2/26/2025Q4 2024
ZimVie Inc. stock logo
ZIMV
ZimVie
$0.25$0.27+$0.02-$0.43$113.67 million$111.52 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
InMode Ltd. stock logo
INMD
InMode
N/AN/AN/AN/AN/A
MiMedx Group, Inc. stock logo
MDXG
MiMedx Group
N/AN/AN/AN/AN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.03
2.78
1.78
InMode Ltd. stock logo
INMD
InMode
N/A
10.23
9.38
MiMedx Group, Inc. stock logo
MDXG
MiMedx Group
0.10
4.10
3.53
ZimVie Inc. stock logo
ZIMV
ZimVie
0.57
1.94
1.38

Institutional Ownership

CompanyInstitutional Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
InMode Ltd. stock logo
INMD
InMode
68.04%
MiMedx Group, Inc. stock logo
MDXG
MiMedx Group
79.15%
ZimVie Inc. stock logo
ZIMV
ZimVie
95.63%

Insider Ownership

CompanyInsider Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.20%
InMode Ltd. stock logo
INMD
InMode
6.92%
MiMedx Group, Inc. stock logo
MDXG
MiMedx Group
1.30%
ZimVie Inc. stock logo
ZIMV
ZimVie
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
44047.50 million45.37 millionOptionable
InMode Ltd. stock logo
INMD
InMode
48069.56 million64.75 millionOptionable
MiMedx Group, Inc. stock logo
MDXG
MiMedx Group
870147.37 million145.04 millionOptionable
ZimVie Inc. stock logo
ZIMV
ZimVie
2,70027.85 million26.77 millionOptionable

Recent News About These Companies

Zimmer Biomet Hits 34th 52-Week Low: Value Play or Value Trap?
What is B. Riley's Forecast for ZimVie Q1 Earnings?
ZimVie (NASDAQ:ZIMV) Coverage Initiated at B. Riley
Needham Remains a Hold on ZimVie Inc (ZIMV)
ZimVie initiated with a Buy at B. Riley
ZimVie shuffles board of directors
Needham Downgrades ZimVie (ZIMV)

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioLife Solutions stock logo

BioLife Solutions NASDAQ:BLFS

$21.91 -0.35 (-1.57%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$21.89 -0.02 (-0.09%)
As of 04/17/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

InMode stock logo

InMode NASDAQ:INMD

$14.92 +0.01 (+0.07%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$14.92 +0.01 (+0.03%)
As of 04/17/2025 05:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

MiMedx Group stock logo

MiMedx Group NASDAQ:MDXG

$6.68 +0.05 (+0.68%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$6.67 0.00 (-0.07%)
As of 04/17/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

ZimVie stock logo

ZimVie NASDAQ:ZIMV

$9.39 +0.14 (+1.51%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$9.39 0.00 (0.00%)
As of 04/17/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment. The company offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. In addition, the company designs, manufactures, and distributes spinal fusion implants, instrumentation for various spinal procedures, biologics, and bone healing technologies. Further, it provides MIS solutions that deliver implant and instrumentation systems; and motion preservation solutions that offer non-fusion alternatives for cervical disc implant or growth modulation for anterior vertebral body tethering. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.